Effect of Nebivolol on serum blood sugar and lipid profile in T2DM patients with mild to moderate hypertension.

Abstract

Objective: To determine the effect of nebivolol on serum lipid profile and glycemic control in T2DM patients with mild to moderate hypertension. Study Design: Randomized Controlled Trial. Setting: Sheikh Zayed Medical College & Hospital Rahim Yar Khan. Period: November 2020 to January 2021. Material & Methods: T2DM patients with mild to moderate hypertension were randomly divided in to two groups to give nebivolol and atenolol. Blood pressure, fasting blood sugar and serum lipid profile were analyzed pre and post treatment by using SPSS 21. Results: After 12 weeks of treatment blood pressure was significantly reduced in both study group i.e nebivolol (SBP from 155±15 to 128±12 p=0.001 and DBP from 90±12.5 to 81±8.5 with p =0.004). Atenolol (SBP from 159±11.0 to 132±9.5 p=0.001 DBP from 92±8.0 to 79±9.5 p=0.002). However no significant changes were observed in SBP and DBP between two groups p=0.32 and p=0.72 respectively. No significant changes observed in glycemic control in both study groups. Nebivolol (HbA1c from 8.5±3.0 to 8.0 ±4.2 p=0.72) Atenolol (HbA1C from 8.2±4.2 to 8.5±3.5 p=0.72). However in comparison with nebivolol, atenolol significantly deteriorates blood sugar and HbA1c with p value 0.002 and 0.0016 respectively. There were no significant changes observed in terms of lipid profile in both study groups. However in comparison with nebivolol, atenolol deteriorates serum lipid profile with significant p values i.e total Cholesterol (0.004), triglycerides (0.006), LDL-Cholesterol (0.002) and HDL-Cholesterol (0.008). Conclusion: Nebivolol has a neutral effect on glycemic control and serum lipid profile in T2DM patients with mild to moderate hypertension.